Established Patient-Derived Xenograft (PDX) Models

LIDE has established 1600+ high quality PDX models in more than 40 cancer types – one of the largest coverage of any PDX bio bank in the world.

Cancer No.  Cancer No. Cancer No.
Pancreatic 299 Sarcoma 26 AML 13
Gastric 193 Cervical 16 ALL 9
Ovarian 186 Endometrial 15 MM 3
Lung 145 Duodenum 14 Neuroendocrine 4
Colon 102 Lymphoma 14 Bladder 4
Hepatocellular 96 HNC 6 Malignant pleural mesothel 2
Cholanglocarcinoma 78 Renal 7 Penile 2
Rectal 69 Mucinous carcinoma 5 Fallopian tube carcinoma 2
Glioblastoma 68 Prostate 7 Paget's Disease 1
Osteosarcoma 42 GIST 6 SCPF 1
Breast 41 ACC 5 Spleen 1
Esophageal 41 Urethral 3 MGST 1
Gallblader 35 Periampullary 2 Chordoma 1
Hepatoblastoma 36 Melanoma 2    

Table: Summary of available PDX Models

Leverage our patient derived xenograft models and partner with LIDE on your next oncology research project:

Application of PDX models in drug R&D

Fig. Schematic of oncology R&D projects available through PDX models

Search our Model Library here

Download a LIDE PDX FactSheet

 

Why LIDE Models:

  1. Many models of rare indications, drug resistant or relapsed/recurrent cancer
    Because we have a MiniPDX® testing program with hospitals all over China, LIDE has been able to amass a large collection of rare 3R (resistant, relapsed, recurrent) models for testing of potential 2nd or 3rd line treatments.
  2. Highly-specific molecular targets and hard to find genetic alterations
    LIDE has validated 200+ special drug resistant and/or genetic altered PDX models, including EGFR single/double/triple mutations in lung cancer, triple negative breast cancer, and models with KRAS mutation, HER2 amplification, or ALK/ROS1/NTRK fusion, etc.
     
    Cancer Type Resistant to Specific Genetic Alteration
    NSCLC Eriotinib
    Osimertinib
    Crizotinib
    Brigatinib
    anti PD-L1 ab
    EGFR: exon19del/T790M/L858R/exon20ins/ C797S
    ALK: EML4-ALK/L1196M
    cMET: ampli./exon14ski/CD47-MET
    RET: KIF5B-RET
    ROS1: CD74-ROS1/G2032R
    KRAS: G12C
    PTEN: Y68X
    P13K: E726K
    Breast Cancer CDK4/6i TNBC/ER+
    Multiple Myeloma Bortezemonib CD47+/CD38+
    Cholangiocarcinoma Paclitaxel KRAS: G12C
    FGFR: BICC1-FGFR2
    Colorectal Cancer Avastin KRAS: G12C
    BRAF: V600E
    Hematological Malignancy Rituximab
    Imatinib
    /
    Gastric Cancer Herceptin HER2: ampli
    KRAS: G12C
    Brain Cancer / EGFR: VII
    cMET: PTPRZ1-MET
    Melanoma anti PD-1 ab BRAF: V600E
    Ovarian Cancer Platinum
    PARPi
    /
    Table: LIDE resistant and genetically modified PDX models
     
  3. Highest testing standards
    Pathological analysis will be done using H&E staining from FFPE reserved during each passage of individual PDX models by a certified pathologist under the U.S. CAP standard. WES and RNAseq will be done in most of the established models according to the highest international standards of PDX Consortium.

    Highest testing standards
     

    Download a LIDE PDX FactSheet